Failure to halt the progression of multiple sclerosis (MS) with immunomodulatory agents and recent pathological insights has shown neurodegeneration to be an important pathogenic component of MS [1] [2] [3] and provides impetus for designing and assessing treatment paradigms in animal models. Axonal loss correlates with permanent neurological disability in chronic relapsing experimental allergic encephalomyelitis (CREAE) [1] and is typically assessed using time-consuming and observer-dependent immunocytochemistry [1, 2] . Therefore simple quantitative surrogates for neurodegeneration would be useful.
In immunocytochemistry, GFAP has been used as a marker for astrogliosis and S100B for activation of astrocytes, ferritin as a marker for microglial activation and neurofilaments (Nf) as a marker for axonal damage [3] [4] [5] [6] . This study examines the potential of ELISA-based methods to assess neurodegeneration in CREAE.
Methods
Adult Biozzi ABH mice (6-8 weeks old) were housed in a light-and temperature -controlled room and matched for age and sex in the experiment (50% female in the CREAE and 43% female in the control group). CREAE was induced as described previously [7] . In brief: Animals were injected s.c. in 2 sites of the flank with a total of 0.3ml of Freund's adjuvant:PBS (1:1) containing 1mg of syngeneic mouse spinal cord homogenate emulsified in Freund's incomplete adjuvant supplemented with 60g mycobacteria (Mycobacterium tuberculosis H37Ra and M.butyricum (8:1)on day 0 and again on day 7. Animals were scored clinically on a scale ranging from 0 to 6, where 0 indicated a normal animal, 1 a limp tail, 2 loss of the inverted righting reflex, 3 par-tial hind limb paralysis, 4 complete hindlimb paralysis, 5 moribund and 6 death [7] . After 60-80 days post-inoculation, the chronic phase of the disease had been reached [8] and the animals were killed by CO 2 intoxication. Immediately after death the spinal column was cut in the cervical and lumbar regions. A needle was inserted into the lumbar vertebral column and the spinal cord ejected into an Eppendorf tube by a pressurised injection of saline. The spinal cord which is the primary site of pathology in this model, [7] was snapfrozen and stored at -70
• C until further analysis. Frozen tissue was used for immunocytochemistry as described using polyclonal rabbit anti-cow GFAP IgG (DAKO, Denmark) or polyclonal rabbit anti-bovine NfH IgG (Sigma, UK) and FITC labelled swine anti-rabbit IgG (Dako) [7, 8] . Photographs of the fluorescien images were digitally transformed into black-and-white slides for better visualisation. prior to centrifugation at 20,000 g. The supernatant was stored at -70
S100B, GFAP and ferritin were measured as described [9, 10, 6] . 
Results
A 3-fold increase of median GFAP levels (13 ng/mg protein) in chronic EAE animals was observed if compared to control animals (4.5 ng/mg protein, Fig.   1 A) . In addition a more intense immunocytochemical staining was observed in CREAE mice. The white matter of CREAE animals showed intense staining for GFAP and widespread astrogliosis. Astrocytes of the CREAE grey matter were of larger configuration with a greater number of extending processes (Figure 2 A) .
Levels of NfH
SMI35 were approximately 3-fold lower in CREAE (21 ng/mg protein) than in control mice (63 ng/mg protein, Fig. 1 B) . The staining for
NfH was more intense in the white matter of control animals (Figure 2 B) . It is of note that the continuity of axonal projections could be followed. In CREAE animals NfH staining was less intense, axonal continuity almost disappeared and many axonal end-bulbs were observed (Figure 2 B) .
Ferritin was less then 2-fold lower in CREAE (547 ng/mg protein) compared to CTRL mice (858 ng/mg protein, Fig. 1 C) , median S100B levels were about 2.6-fold lower in CREAE (786 ng/mg protein) than in CTRL mice (2080 ng/mg protein, Fig. 1 D) .
Seven out of 8 (88%) CREAE animals had GFAP levels above the cut-off and by definition none (0%) of the control animals had GFAP levels above the cut-off (p<0.001). For NfH SMI35 0/8 (0%) of the CREAE and 7/7 (100%) of the control animals had levels above the cut-off (p<0.001). For ferritin 1/7 (13%) of the CREAE and 7/7 (100%) of the control mice had levels above cutoff (p<0.001). For S100B 3/8 (38%) of the CREAE and 0/7 (100%) of the control mice had levels above the cut-off, but this did not reach statistical significance. For the small number of animals investigated we found no statistically significant difference in proportions of animals with moderately (score ≤ 4) vesus severe (score of 5) disability.
3 Discussion
The observation that GFAP levels were 3-fold higher in the spinal cords of mice with chronic EAE compared to control animals is in keeping with the observation that extensive gliosis is a pathological hallmark of the late stages of the disease [4, 7] . However gliosis is difficult to quantify by immuncytochemical techniques and usually done by counting cells, and the number and length of extending processes. The finding of grey matter astrogliosis and elevated GFAP levels is in line with previous results from human multiple sclerosis post-mortem tissue [6] .
NfH SMI35 levels were significantly lower in chronic EAE animals when compared to control animals. This biochemical result confirms the immunocytochemical observation of loss of axons in these animals [7, 1] . In the light of recent data on axonal loss in MS [2, 3] and severe axonal loss in the spinal cord of EAE [1] , it is of particular interest that not only the overall staining intensity for NfH decreased, but also that axonal continuity almost completely disappeared. Counting axons might be particularly difficult in these situations and would only represent an estimate at the site of section. The measurement of the total NfH SMI35 content is likely to be a more robust overall estimate of the bulk of remaining axons.
Ferritin and S100B are distinct from GFAP and NfH SMI35 since they do not provide the scaffolding of the cytoskeleton, but are a product of the cellular metabolism for specific functional purposes. The decrease of ferritin suggests that the gliotic tissue transformation is paralleled by specific alteration of the glial metabolism. Whether or not this involves loss of neurotrophic support will need to be studied in experiments focusing on neurodegeneration.
In summary these findings demonstrate that axonal loss and gliosis can be quantified biochemically by measuring NfH SMI35 and GFAP levels in the spinal cord tissue homogenate of animals with CREAE. These findings support the notion that brain-specific proteins emerge as surrogate markers and secondary outcome measures for neurodegenerative processes. The methods presented should be cross-validated with other markers and may provide time-and costeffective tools for experimental models investigating neurodegeneration. 
